复旦张江：获得药物临床试验申请受理通知书

Group 1 - The core point of the article is that Fudan Zhangjiang (688505) has received approval from the National Medical Products Administration for the clinical trial application of FZ-P001 sodium for visualizing malignant lesions in known or suspected lung cancer patients during surgery [1] Group 2 - The clinical trial is categorized as a Phase II trial, indicating that it is in the second stage of testing for safety and efficacy [1]